The future discontinuation of chlorofluorocarbon (CFC)-containing inhalers will affect the range of devices available, but does not affect this guidance.
For adults and children aged 12 years and older with chronic asthma in whom treatment with an inhaled corticosteroid (ICS) is considered appropriate, the least costly product that is suitable for an individual, within its marketing authorisation, is recommended.
For adults and children aged 12 years and older with chronic asthma in whom treatment with an ICS and long-acting beta-2 agonist (LABA) is considered appropriate, the following apply.
The use of a combination device within its marketing authorisation is recommended as an option.
The decision to use a combination device or the 2 agents in separate devices should be made on an individual basis, taking into consideration therapeutic need and the likelihood of treatment adherence.
If a combination device is chosen then the least costly device that is suitable for the individual is recommended.